<DOC>
	<DOCNO>NCT03002064</DOCNO>
	<brief_summary>This phase III clinical trial compare efficacy docetaxel plus cisplatin versus 5-Fu plus cisplatin first line chemotherapy advance metastatic esophageal squamous carcinoma patient .</brief_summary>
	<brief_title>Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin 1st-line Chemotherapy Advanced ESCC Patients</brief_title>
	<detailed_description>Esophageal cancer 6th common cause cancer death worldwide endemic many part world , particularly develop country , include China . Histologically , esophageal cancer classify adenocarcinoma esophageal squamous cell . carcinoma ( ESCC ) common histology Asia . For locally advanced metastatic ESCC patient , chemotherapy improve overall survival ( OS ) progression free survival ( PFS ) . There standard first-line chemotherapy ESCC patient . Cisplatin ( DDP ) plus fluorouracil common use combination response rate 25-35 % . Previous study show combination paclitaxel cisplatin good tolerance efficacy esophageal carcinoma . This prospective randomize control phase III clinical trial compare efficacy safety docetaxel/cisplatin 5-Fu/cisplatin 1st line treatment advance metastatic esophageal carcinoma patient . Sample size : This non-inferior study . The planned sample size 358 patient , allow 10 % dropout rate assume median progression free survival 5.5 month experimental group 4 month control group hazard ratio 0.727 , α=0.05 , β=0.2 . The plan enrol time 36 month 12 month follow . The ratio control experimental group 1:1 .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients must give write informed consent sign voluntarily patient supervisor witted doctor . 2 . Patients must histologically confirm esophageal squamous cell carcinoma without prior treatment include surgery , chemotherapy , radiotherapy , target treatment . Patients allow palliative radiotherapy 3 month enrollment target lesion within radiotherapy region . The last date adjuvant therapy 6 month enrollment . 3 . With measurable evaluable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . 4 . With expect life expectancy ≥ 3 month . 5 . With performance status 01 Eastern Cooperative Oncology Group ( ECOG ) scale . 6 . Without serious system dysfunction could tolerate chemotherapy . 7 . Patients must normal bone marrow function hemoglobin ( HGB ) ≥90g/L , white blood cell ( WBC ) count ≥4.0×10^9/L，a neutrophil count ≥2.0×10^9/L , , platelet count ≥100×10^9/L . 8 . Patients must normal liver renal function total bilirubin ( TBil ) ≤1.5 upper normal limitation ( UNL ) , creatinine ( Cr ) ≤ 1.0 UNL , alanine aminotransferase ( ALAT ) aspartate aminotransferase ( ASAT ) ≤2.5 UNL . 9 . Patients must normal electrocardiogram result history congestive heart failure . 10 . Women childbearing age voluntarily take contraceptive measure . Without drug addition 11 . Patients must good compliance agree accept followup disease progression adverse event . 1 . Allergic known drug 2 . Patients receive prior treatment include chemotherapy , radiotherapy surgery advance metastatic disease . 3 . Receive docetaxel within 6 month adjuvant neoadjuvant chemotherapy . 4 . Brain metastasis . 5 . Without measurable evaluable disease . 6 . With history tumor except cervical carcinoma situ skin basal cell carcinoma completely treat without relapse last 5 year . 7 . With serious disease congestive heart failure , uncontrolled myocardial infarction arrhythmia , liver failure renal failure . 8 . With neurological psychiatric abnormality affect cognitive . 9 . Pregnant lactate woman ( premenopausal woman must give urine pregnancy test enrollment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Esophagus squamous carcinoma</keyword>
	<keyword>First-line chemotherapy</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>5-fluorouracil</keyword>
</DOC>